Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) - Kawaguchi, T; Ando, M; Asami, K (J Clin Oncol, 2014)
, et al.